Accès ouvert déclaré
2025
article
Circulating HBV RNA and hepatitis B core-related antigen as determinants of HBsAg loss in persons with HIV in Europe
Lorin Begré, Anders Boyd, Marie‐Laure Plissonnier, Barbara Testoni, Charles Béguelin, Franziska Suter‐Riniker, Caroline Scholtès, Karine Lacombe, Lars Peters, Marintha Heil, Massimo Levrero, Fabien Zoulim, Gilles Wandeler, Heiner C. Bucher, Christian R. Kahlert, Arjan Harxhi, M. Losso, M Kundro, Michael Knappik, Piotr Cichon, Klinik Penzing, M. Sarcletti, Igor Karpov, В. М. Мицура, D. Paduto, Nathan Clumeck, M. Delforge, Maartje Van Frankenhuijsen, Marie‐Angélique De Scheerder, J. Topalovic, J. Begovac, David Jilich, Ladislav Machala, Dalibor Sedláček, Thomas Benfield, Jan Gerstoft, Anne‐Mette Lebech, Ole Kirk, Işık Somuncu Johansen, Lothar Wiese, Lise Nikolic Nielsen, K. Zilmer, Viard Jp, Éric Fontas, Claudine Duvivier, Jürgen K. Rockstroh, Olaf Degen, Christian Hoffmann, Christopher J. Stefan, Johannes R. Bogner, Clara Lehmann, Akaki Abutidze, H Sambatakou, Georgios Adamis, N. Paissios, János Szlávik, Magnús Gottfreðsson, E. Devitt, O.V. Bondarenko, L.M. Wattad, Hila Elinav, Daniel Elbirt, Giulia Marchetti, G. Guaraldi, C Mussini, Antonella Castagna, Anna Lisa Ridolfo, Filippo Schiavo, Vilma Uždavinienė, Raimonda Matulionytė, Thérèse Staub, R. Batutu, J. Trajanovska, Dag Henrik Reikvam, Brygida Knysz, Bartosz Szetela, Małgorzata Inglot, Elżbieta Bąkowska, Miłosz Parczewski, Bogusz Aksak‐Wąs, Marek Beniowski, E. Mularska, Elżbieta Jabłonowska, Juliusz Kamerys, Kamila Wójcik, Iwona Mozer‐Lisewska, Błażej Rozpłochowski, Alexandra Zagalo, K. Mansinho, Fernando Maltêz, Roxana Rădoi, C. Oprea, Д. А. Гусев, T. Trofimova, Elena Kuzovatova, Е. А. Бородулина, Е. С. Вдоушкина, Jovan Ranin, Janez Tomažič, Elisa Martínez, José M. Miró, Montserrat Laguno, José Luís Blanco, Maria Martínez‐Rebollar, Juan Ambrosioni, Berta Torres, Ana Gonzalez‐Cordón, Iván Chivite, Alberto Foncillas, E. de Lazzaari, Leire Berrocal, Pilar Callau, Alexy Inciarte, José Alcamı́, Josep Mallolas, Roger Paredes, Javier Juega Puig, José Ramón Santos, Carolina Miranda, Peré Domingo, Guang-Yuan Mar, María Pilar Rivero Gracia, Ester Sáez de Adana Arróniz, Anders Sönnerborg, Johanna Brännström, Karolin Falconer, Fredrik Månsson, Katharina Kusejko, Alexandra Calmy, H Furrer, Manuel Battegay, Patrick Schmid, Enos Bernasconi, Anastasiia Kuznetsova, Larisa Hetman, Alina Kryshchuk, Marta Boffito, Simon Edwards, Fiona Burns, C. Orkin, Alan Winston, Amy L. Clarke, CG Mackintosh, Christoph Boesecke, Eduardo Martínez, J. Lundgren, Lasse Dam Rasmussen, О. В. Нестерова, Silvia Nozza, Jens Fromholt Larsen, Masyar Gardizi, Nadine Jaschinski, A Timiryasova, Bastian Neesgaard, F. Roper, David Raben, Andrew H. Fischer, Alessandro Cozzi‐Lepri, Wade Bannister, T W Elsing, Lalit Kumar, S. Shahi, Brandon Elliott Pepa, Patrick Miailhes, Caroline Lascoux‐Combe, Julie Chas, Pierre‐Marie Girard, Joël Gozlan, Constance Delaugerre, Hayette Rougier
1Citations signalées — pas une note de qualité
19Institutions déclarées
7Pays d’affiliation déclarés
Résumé fourni par la source
Background & Aims: HBsAg loss improves clinical outcomes in persons with HIV and HBV coinfection. We aimed to evaluate if hepatitis B core-related antigen and circulating HBV RNA levels were associated with HBsAg loss in Euro-B, a multi-cohort collaboration including data from the Swiss HIV Cohort Study, EuroSIDA, and the French HIV/HBV cohort. Methods: quantitative HBsAg <0.05 IU/ml) during tenofovir therapy. Results: Among 599 participants median age was 41 years (IQR 35-47), 18.4% were female and 47.3% HBeAg-positive. We observed HBsAg loss in 12.9% of participants after 2 years and in 18.2% during a median follow-up of 8.2 years (IQR 3.6-13.1). Individuals who were HBeAg-negative were more likely to have a negative hepatitis B core-related antigen and HBV RNA below the detection limit than participants who were HBeAg-positive. Quantitative HBsAg ≤1,000 IU/ml at baseline was the strongest predictor of HBsAg loss regardless of HBeAg status. Additionally, HBsAg loss was associated with lower baseline HBV RNA levels (odds ratio 0.66, 95% CI 0.49-0.88) and higher baseline HBV DNA levels in participants who were HBeAg-positive. Conclusions: In this European cohort of persons with HIV/HBV, 18% experienced HBsAg loss during tenofovir-containing antiretroviral therapy. In addition to low baseline quantitative HBsAg levels, HBV RNA may predict HBsAg loss in individuals who are HBeAg-positive. Impact and implications: The present study builds on a multi-cohort collaboration including persons with HIV/HBV from Europe. It provides estimates on the probability of HBsAg loss during long-term tenofovir-containing antiretroviral therapy and describes the potential of the novel biomarkers HBV RNA and hepatitis B core-related antigen as its predictors. The discrepancies regarding HBV RNA and HBcrAg levels before and during therapy observed between persons who were HBeAg-negative and HBeAg-positive with HIV/HBV may influence treatment decisions and the development of new treatment strategies. Clinical Trials Registration: The study is registered at ClinicalTrials.gov (NCT04984772).
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Circulating HBV RNA and hepatitis B core-related antigen as determinants of HBsAg loss in persons with HIV in Europe
- Date Crossref
- 01/02/2026
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude et ne compte pas comme une seconde source scientifique indépendante.
Institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Sujets associés
Hepatitis B Virus StudiesHIV Research and TreatmentHepatitis C virus research